CA3219130A1 - Systemes et methodes d'administration de therapie medicamenteuse - Google Patents
Systemes et methodes d'administration de therapie medicamenteuse Download PDFInfo
- Publication number
- CA3219130A1 CA3219130A1 CA3219130A CA3219130A CA3219130A1 CA 3219130 A1 CA3219130 A1 CA 3219130A1 CA 3219130 A CA3219130 A CA 3219130A CA 3219130 A CA3219130 A CA 3219130A CA 3219130 A1 CA3219130 A1 CA 3219130A1
- Authority
- CA
- Canada
- Prior art keywords
- medicament
- reservoir
- state
- pharmaceutical composition
- dispensing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 148
- 238000002651 drug therapy Methods 0.000 title description 4
- 239000003814 drug Substances 0.000 claims abstract description 1018
- 239000012229 microporous material Substances 0.000 claims abstract description 221
- 239000011148 porous material Substances 0.000 claims abstract description 133
- 239000000463 material Substances 0.000 claims description 122
- 238000011282 treatment Methods 0.000 claims description 103
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 95
- 239000012530 fluid Substances 0.000 claims description 95
- 238000002513 implantation Methods 0.000 claims description 94
- 201000010099 disease Diseases 0.000 claims description 93
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 72
- 229940124597 therapeutic agent Drugs 0.000 claims description 71
- 239000008194 pharmaceutical composition Substances 0.000 claims description 69
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 40
- 238000004891 communication Methods 0.000 claims description 32
- 208000002780 macular degeneration Diseases 0.000 claims description 32
- 206010038910 Retinitis Diseases 0.000 claims description 30
- 208000001344 Macular Edema Diseases 0.000 claims description 29
- 206010025415 Macular oedema Diseases 0.000 claims description 29
- 201000010230 macular retinal edema Diseases 0.000 claims description 29
- 208000010412 Glaucoma Diseases 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- 206010023332 keratitis Diseases 0.000 claims description 25
- 206010046851 Uveitis Diseases 0.000 claims description 22
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 21
- 206010013774 Dry eye Diseases 0.000 claims description 21
- 238000011049 filling Methods 0.000 claims description 21
- 239000002876 beta blocker Substances 0.000 claims description 20
- 229940097320 beta blocking agent Drugs 0.000 claims description 20
- 150000003180 prostaglandins Chemical class 0.000 claims description 20
- 150000003431 steroids Chemical class 0.000 claims description 20
- 239000000556 agonist Substances 0.000 claims description 19
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims description 18
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 18
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 17
- 201000010041 presbyopia Diseases 0.000 claims description 17
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 201000000582 Retinoblastoma Diseases 0.000 claims description 15
- 230000033001 locomotion Effects 0.000 claims description 15
- 239000011859 microparticle Substances 0.000 claims description 15
- 230000007704 transition Effects 0.000 claims description 15
- 238000001415 gene therapy Methods 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 208000030533 eye disease Diseases 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 11
- 229960001160 latanoprost Drugs 0.000 claims description 11
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 10
- 229960003933 dorzolamide Drugs 0.000 claims description 10
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims description 10
- 229960004605 timolol Drugs 0.000 claims description 10
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 9
- 229960003679 brimonidine Drugs 0.000 claims description 9
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 7
- 229940121357 antivirals Drugs 0.000 claims description 7
- 239000003246 corticosteroid Substances 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000003429 antifungal agent Substances 0.000 claims description 5
- 230000003547 miosis Effects 0.000 claims description 5
- 239000003604 miotic agent Substances 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 230000002459 sustained effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 3
- 235000005822 corn Nutrition 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 description 183
- 210000001519 tissue Anatomy 0.000 description 150
- 230000002265 prevention Effects 0.000 description 40
- 230000001413 cellular effect Effects 0.000 description 35
- 230000008595 infiltration Effects 0.000 description 33
- 238000001764 infiltration Methods 0.000 description 33
- 230000006870 function Effects 0.000 description 31
- 238000011065 in-situ storage Methods 0.000 description 30
- 238000003780 insertion Methods 0.000 description 30
- 230000037431 insertion Effects 0.000 description 30
- 238000012377 drug delivery Methods 0.000 description 20
- 230000035699 permeability Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 210000002159 anterior chamber Anatomy 0.000 description 18
- 239000002245 particle Substances 0.000 description 15
- 230000002093 peripheral effect Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 238000001125 extrusion Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 230000001788 irregular Effects 0.000 description 10
- 238000000576 coating method Methods 0.000 description 9
- 210000000795 conjunctiva Anatomy 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 238000005452 bending Methods 0.000 description 8
- 229920001296 polysiloxane Polymers 0.000 description 8
- 210000003786 sclera Anatomy 0.000 description 8
- 239000003566 sealing material Substances 0.000 description 8
- 210000003484 anatomy Anatomy 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 208000017442 Retinal disease Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000013536 elastomeric material Substances 0.000 description 6
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 5
- 239000000560 biocompatible material Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- -1 polyhexafluoropropylene Polymers 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 206010030043 Ocular hypertension Diseases 0.000 description 4
- 229960002470 bimatoprost Drugs 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000000806 elastomer Substances 0.000 description 4
- 210000000887 face Anatomy 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960004716 idoxuridine Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 229940061341 retisert Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 229920000249 biocompatible polymer Polymers 0.000 description 3
- 230000004397 blinking Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 201000011190 diabetic macular edema Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940076783 lucentis Drugs 0.000 description 3
- 229940083224 ozurdex Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 229960003876 ranibizumab Drugs 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- BLTXWCKMNMYXEA-UHFFFAOYSA-N 1,1,2-trifluoro-2-(trifluoromethoxy)ethene Chemical compound FC(F)=C(F)OC(F)(F)F BLTXWCKMNMYXEA-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 208000021921 corneal disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229940051306 eylea Drugs 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960002368 travoprost Drugs 0.000 description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229940053728 vitrasert Drugs 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 239000004687 Nylon copolymer Substances 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241000083513 Punctum Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 229940059222 betimol Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002164 blood-aqueous barrier Anatomy 0.000 description 1
- 230000004420 blood-aqueous barrier Effects 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WDRFFJWBUDTUCA-UHFFFAOYSA-N chlorhexidine acetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 1
- 229960001884 chlorhexidine diacetate Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- FHTQCUNSKSWOHF-UHFFFAOYSA-N ethyl carbamate;silicon Chemical compound [Si].CCOC(N)=O FHTQCUNSKSWOHF-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229920001973 fluoroelastomer Polymers 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002453 idose derivatives Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229960005381 lifitegrast Drugs 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
- 229940023106 xiidra Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
L'invention concerne un dispositif d'administration implantable servant à distribuer un médicament qui comprend un premier matériau microporeux qui est lié à un second matériau microporeux. Le premier matériau microporeux comporte une première couche microporeuse comprenant une pluralité de pores dimensionnés de façon à permettre l'interposition d'un tissu et une deuxième couche microporeuse comprenant une pluralité de pores dimensionnés de façon à permettre l'interposition d'un tissu. Le second matériau microporeux comporte une troisième couche microporeuse comprenant une pluralité de pores dimensionnés de façon à résister à l'interposition d'un tissu et une quatrième couche microporeuse comprenant une pluralité de pores dimensionnés de façon à permettre l'interposition d'un tissu. La deuxième couche microporeuse est liée à la troisième couche microporeuse pour former ainsi un réservoir destiné à recevoir le médicament. Le premier et le second matériau microporeux sont conçus pour mesurer une vitesse à laquelle le médicament est distribué à partir du réservoir lorsque le dispositif de distribution est implanté.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194152P | 2021-05-27 | 2021-05-27 | |
| US63/194,152 | 2021-05-27 | ||
| US202263345595P | 2022-05-25 | 2022-05-25 | |
| US63/345,595 | 2022-05-25 | ||
| US17/825,909 | 2022-05-26 | ||
| US17/825,909 US20220378611A1 (en) | 2021-05-27 | 2022-05-26 | Drug therapy delivery systems and methods |
| PCT/US2022/031305 WO2022251603A1 (fr) | 2021-05-27 | 2022-05-27 | Systèmes et méthodes d'administration de thérapie médicamenteuse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219130A1 true CA3219130A1 (fr) | 2022-12-01 |
Family
ID=82067727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219130A Pending CA3219130A1 (fr) | 2021-05-27 | 2022-05-27 | Systemes et methodes d'administration de therapie medicamenteuse |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4346757A1 (fr) |
| JP (1) | JP2024522285A (fr) |
| KR (1) | KR20240013804A (fr) |
| AU (1) | AU2022283386A1 (fr) |
| CA (1) | CA3219130A1 (fr) |
| IL (1) | IL308857A (fr) |
| WO (1) | WO2022251603A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024168118A1 (fr) * | 2023-02-08 | 2024-08-15 | W. L. Gore & Associates, Inc. | Dispositifs et méthodes de drainage de fluide biologique |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316394B1 (fr) * | 2001-06-12 | 2016-11-23 | The Johns Hopkins University | Dispositif à réservoir pour administration intraoculaire de médicaments |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8004920B2 (en) | 2007-05-29 | 2011-08-23 | Micron Technology, Inc. | Power saving memory apparatus, systems, and methods |
| MX2010008998A (es) | 2008-02-18 | 2010-11-26 | Qlt Plug Delivery Inc | Implantes lagrimales y metodos relacionados. |
| WO2012142318A1 (fr) * | 2011-04-14 | 2012-10-18 | The Regents Of The University Of California | Dispositif d'administration d'un médicament constitué de plusieurs pellicules minces, et procédés de fabrication et d'utilisation associés |
| CA2907681C (fr) | 2013-03-28 | 2022-11-22 | Forsight Vision4, Inc. | Implant ophtalmique pour administrer des substances therapeutiques |
| EP2839949B1 (fr) | 2013-08-23 | 2016-10-12 | W.L. Gore & Associates GmbH | Procédé de production d'un film structuré |
| JP6655610B2 (ja) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | 制御された薬物送達機能を備えるインプラント及びそれを使用する方法 |
| US11052230B2 (en) | 2016-11-08 | 2021-07-06 | W. L. Gore & Associates, Inc. | Implantable encapsulation devices |
| US10849731B2 (en) | 2016-11-08 | 2020-12-01 | W. L. Gore & Associates, Inc. | Cell encapsulation devices containing structural spacers |
| US11351058B2 (en) | 2017-03-17 | 2022-06-07 | W. L. Gore & Associates, Inc. | Glaucoma treatment systems and methods |
| CN112996468A (zh) * | 2018-08-29 | 2021-06-18 | W.L.戈尔及同仁股份有限公司 | 药物治疗递送系统和方法 |
-
2022
- 2022-05-27 CA CA3219130A patent/CA3219130A1/fr active Pending
- 2022-05-27 EP EP22731025.7A patent/EP4346757A1/fr active Pending
- 2022-05-27 IL IL308857A patent/IL308857A/en unknown
- 2022-05-27 AU AU2022283386A patent/AU2022283386A1/en active Pending
- 2022-05-27 WO PCT/US2022/031305 patent/WO2022251603A1/fr active Application Filing
- 2022-05-27 KR KR1020237044922A patent/KR20240013804A/ko unknown
- 2022-05-27 JP JP2023573186A patent/JP2024522285A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024522285A (ja) | 2024-06-13 |
| IL308857A (en) | 2024-01-01 |
| KR20240013804A (ko) | 2024-01-30 |
| WO2022251603A1 (fr) | 2022-12-01 |
| EP4346757A1 (fr) | 2024-04-10 |
| AU2022283386A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7507807B2 (ja) | 薬剤溶出眼内インプラント | |
| JP5662436B2 (ja) | 軟組織において空間を維持する繊維マトリックス | |
| JP4677538B2 (ja) | 眼内薬物送達のためのリザーバデバイス | |
| US20100114309A1 (en) | Drug delivery implants for inhibition of optical defects | |
| CN104168863A (zh) | 用于治疗青光眼的方法、外科手术套件及装置 | |
| AU2019333136B2 (en) | Drug therapy delivery systems and methods | |
| CA3219130A1 (fr) | Systemes et methodes d'administration de therapie medicamenteuse | |
| US20220378611A1 (en) | Drug therapy delivery systems and methods | |
| CN117729912A (zh) | 药品治疗递送系统和方法 | |
| US20240041645A1 (en) | Medicament therapy delivery systems and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231130 |
|
| EEER | Examination request |
Effective date: 20231130 |